CHAPTER ONE

Introduction

Table 01 List of Hematopoietic cell markers 43
Table 02 Hematopoietic transcription factors 43
Table 03 Symptoms of CML 43
Table 04 Prognostic factors of CML 43
Table 05 Predictors of therapeutic outcome in CML 43
Table 06 Blast counts in CML 44
Table 07 Therapeutic responses in CML 44
Table 08 Non-coding RNAs types and function 44
Table 09 Characteristics of standard nuclease platforms 44

CHAPTER TWO

Materials and methods

Table 2.1 List of guide RNAs to target MIR182 locus 52
Table 2.2 Primer sequences to amplify MIR182 target sites 52
Table 2.3 Primer sequences to amplify MIR182 locus 52

CHAPTER THREE

Targeting Cancerous Cells Effect of Marine Extracts and TK Inhibitors

CHAPTER FOUR

High throughput approaches to understand the TKI resistance in CML

Table 4.1 Normalised fold change in the expression of miRNAs in control and Imatinib treated K562 cells 85
Table 4.2 Clinical details of patients with CML 87

CHAPTER FIVE

Functional Characterization of MiRNA182 Signalling Components

CHAPTER SIX

CRISPR Knockout of MIR182 and Properties of Δ182 cells

Table 6.1 Off-targets of CRISPR guide RNAs targeting MIR182 locus 111

CHAPTER SEVEN

Summary and Discussion